Overexpression of hENT1 enhances gemcitabine response in human pancreatic cancer, and cells lacking hENT1 expression are highly resistant to gemcitabine (Mori et al., 2007; Perez-Torras et al., 2008, 2013). This evidence concerns the gene SLC29A1 and familial pancreatic carcinoma.